IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
© 2021. The Author(s)..
The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Cellular & molecular immunology - 19(2022), 1 vom: 12. Jan., Seite 23-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Wan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
82115-62-6 |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 17.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41423-021-00735-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329294113 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329294113 | ||
| 003 | DE-627 | ||
| 005 | 20231225204813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41423-021-00735-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329294113 | ||
| 035 | |a (NLM)34385592 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Du, Wan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IFNγ signaling integrity in colorectal cancer immunity and immunotherapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 17.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ARID1A | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a EZH2 | |
| 650 | 4 | |a Ferroptosis | |
| 650 | 4 | |a IFNGR | |
| 650 | 4 | |a Immunity | |
| 650 | 4 | |a Interferon | |
| 650 | 4 | |a MHC | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Palmitoylation | |
| 650 | 4 | |a T cell | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 700 | 1 | |a Frankel, Timothy L |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Weiping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular & molecular immunology |d 2004 |g 19(2022), 1 vom: 12. Jan., Seite 23-32 |w (DE-627)NLM158038010 |x 2042-0226 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:1 |g day:12 |g month:01 |g pages:23-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41423-021-00735-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 1 |b 12 |c 01 |h 23-32 | ||